Study why blood cancer returns after donor stem cell transplant
Part of Blood & lymphatic clinical trials.
This study looks at why a bone marrow disorder (MDS) can come back after a donor stem cell transplant. It may help researchers understand relapse, which could improve future care for people getting transplants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with MDS based on the 2016 World Health Organization criteria
- You are 18 years old or older
- You are planning to receive a donor (allogeneic) stem cell transplant
- You can sign consent for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at special stem cells in the blood or bone marrow of people with myelodysplastic syndromes (MDS). It aims to better predict how the disease might progress and help guide treatment decisions.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.